Columbia University

The Maine Cancer Genomics Initiative (MCGI) aims to expand education, clinical trial access, and treatment for Maine oncologists, particularly in rural and underserved areas. MCGI, in collaboration with Columbia University, is studying the impact of Genomic Tumor Boards (GTBs) on cancer care delivery. Additionally, research focuses on HER2 protein's role in cell proliferation and its implications in cancer treatment. The internship highlighted the importance of collaborative networks in addressing healthcare disparities and provided proficiency in data collection and analysis techniques.

Cybin Inc. announces key hires for its Phase 3 pivotal trial of CYB003 in MDD, including Dr. Mirza Rahman and Dr. Marcelo Gutierrez, to support three studies across 12 countries.

A study reveals nearly half of AI medical devices authorized by the FDA lack clinical validation data, raising concerns about their effectiveness and safety. Researchers call for clearer standards in clinical validation, emphasizing the need for the FDA to differentiate among retrospective, prospective, and randomized controlled trials.

Dr. Rachel Brem is featured in the Breakthrough Women in Science & Medicine series for her work on early breast cancer screening. The episode, available from October 5th, discusses breast density awareness and secondary screening methods like MRI and ultrasound. Brem emphasizes the importance of education and advocacy in optimizing breast cancer screening protocols.

Salim and Quarraisha Abdool-Karim won the Lasker Prize for their HIV research, focusing on heterosexual transmission and developing Tenofovir gel to prevent HIV in women. Their work contributed to reducing new HIV infections in South Africa.

3-year results from Ascendis Pharma's Phase 2 PaTH Forward Trial show long-term treatment with TransCon™ PTH (palopegteriparatide) normalized bone remodeling in hypoparathyroidism patients, promoting skeletal health parameters similar to parathyroid sufficiency.

Ascendis Pharma's 3-year Phase 2 PaTH Forward Trial results show long-term TransCon™ PTH treatment normalized bone remodeling in hypoparathyroidism patients, presented by Dr. Mishaela Rubin at ASBMR 2024.